Ozempic is still the GLP-1 king, but Lilly is rapidly gaining market share, with its Q2 2024 sales reaching $3.01 billion compared to Novo Nordisks $5.38 billion
At RazorMetrics, we offer a smarter, easier path: one that supports the physician, respects the member, and reduces unnecessary spend without disrupting clinical care
Pamper your lips with the nourishment they deserve and embrace a transfer-proof, long-wear lip color that's designed to make you feel fabulous all day long
GLP-1 agonist to treat obesity and prevent cardiovascular disease: what have we achieved so far
Recovery: There is no time for recovery as it is a noninvasive injectable process
doi: 10.1093/annonc/mdy495 23 PalmieriGOmbraMColombinoMCasulaMSiniMMancaAet al